

Transitions, Omissions and High Risk Medicine WebEx Series 2018–2019

Bleeds associated with medicines use SPSP Medicines team

Thursday 20 September 2018 3pm-4pm



@SPSPMedicines #SPSPMeds As part of Healthcare Improvement Scotland's ihub, SPSP activities support the provision of safe, high quality care, whatever the setting.



A few points for our WebEx today:

Please dial in on your phone: 0800 032 8069 and then use the pass code: 564 897 14 #

If you are not presenting your phone is automatically on mute

Phone lines will open at the beginning and end of the WebEx for Q and A with the presenter.









Meet the team



Arvind Veiraiah National Clinical Lead

Lorraine Donaldson Project Officer



Kirsty Allan Administrative Officer



Polling Question 1

Which of the following professions best describes you?

- a. Patient / Service User
- b. Medical
- c. Nursing
- d. Pharmacy
- e. Other (please type in chat box)








To get involved in the conversation, please click on the Chat icon.

Select **Everyone** from the drop down menu, type your message then click send. Introduce yourself.

This WebEx is being recorded as a resource and will be available on the ihub website

















Pre-WebEx Question 1

• As a patient/carer or professional, what medicines, through use or non-use, cause the most harms?

If you can, please type in the chat box, describing your setting, your role, and the high-risk medicines in your setting (and why the medicine is high risk if not commonly recognised as such). If you can't type in the chat box, please write down your thoughts if you can – 1 min

• We will discuss your answers after a minute – please feel free to continue typing in the chat box if you wish.







• How do you know which medicines cause the most harms in your setting?

 If you can, please type in the chat box, describing whether your assessment is based on intuition, or on data, and if the latter, please describe how the data are collected. If you can't type in the chat box, please write down your thoughts if you can – 1 min

• We will discuss your answers after a minute – please feel free to continue typing in the chat box if you wish.







Pre-WebEx Question 3

- Please name any harm-reduction steps for specific medicines that you plan to test or implement in the next 6 months.
- If you can, please type in the chat box, describing the medicine(s) and the main intervention(s). If you can't type in the chat box, please write down your thoughts if you can 1 min

• We will discuss your answers after a minute – please feel free to continue typing in the chat box if you wish.







- On the SPSP Medicines agenda since September 2015
- HRM Measures originally considered:
 - 95% of patients on gentamicin and vancomycin within the therapeutic range
 - 30% reduction in INRs which are outwith the range 1.5 6
 - Double number of days between incidences involving high risk drugs
 - 95% of patients on {high risk drug , eg oxytocin} prescribed correct concentration, dose & route







- On the SPSP Medicines agenda since 2015
- "Outcome measures" challenging:
 - Poor recognition & reporting of harm
 - Focus on drugs with narrow therapeutic margins and measurable concentrations
 - Poor adaptation to area of work
- How to engage staff in further work when they were still struggling with "Meds Rec"?








- Other HRM choices:
 - (NSW standards) opiates, methotrexate, neuromuscular blocking drugs, paracetamol,
 IV potassium, vincristine, other anticoagulants

- Dreischulte et al (NHS Tayside) in the DQUIP study explored measures to reduce harm from NSAIDs +/- antiplatelets +/- anticoagulants in "high risk" patients (by age)
- Additional NHS Improvement options valproate, methotrexate, opioids & analgesic infusions, Li, insulin, theophylline, anaethetic medicines, IV potassium, BB in asthma, prolonged antipsychotic (dementia)









Published August 20

Originally produced by and silagrand from NHS England




Medicine or medicine group	Harm (adverse effect or effect of omitted dose(s))	Deterioration (changes that are associated with increased likelihood of harm in that patient)	Interventions to PREVENT deterioration	Interventions to increase RECOGNITION of deterioration	Interventions to improve (structured) RESPONSE to deterioration
		patenty			



Medicine or medicine group	Harm (adverse effect or effect of omitted dose(s))	Deterioration (changes that are associated with increased likelihood of harm in that patient)	Interventions to PREVENT deterioration	Interventions to increase RECOGNITION of deterioration	Interventions to improve (structured) RESPONSE to deterioration
Lithium	ADR - Toxicity Harm from omission In the short term little but sudden drops in serum level associated with greatest risk of relapse compared to reduced compliance with other mood stabilisers	 Dehydration Reduced renal function Interacting medicines Lack of monitoring Transfer to a different area/team Physical illness Changes to salt intake 	- Education for staff - Education for patients & carers - Systematic approach to monitoring including routine serum level on admission (? Done in acute/cottage hospitals) - Standardised approach to SE monitoring	- Choice & Medication website & leaflets - Reinforce at every clinical contact (include community pharmacy here) - Lithium SE check list - Lithium ward bundle	- National monitoring standards (in development with SGHD) - Pre-administration nursing check list -SOP for management of suspected toxicity if not included elsewhere
Clozapine	ADR - Constipation - Weight gain & metabolic syndrome Harm from omission - Inappropriate treatment breaks and significant impact this has e.g. avoidable admission for re-titration and/or relapse	- Change in bowel habit - Abdominal pain - Chronic bowel obstruction - Faecal overflow - type 2 diabetes - Unnecessary admissions to re- establish treatment - Loss of symptom control -Change to smoking status -Interacting medicines - Transfer to a different area/team	- Education -Transfer checklist	- Systematic assessment at every clinical contact -Action at time of change to smoking status (planned or enforced e.g. admission to non- smoking environment)	 Pro-active treatment Standard nursing SE care plan Guidelines Effective medicines reconciliation National clozapine physical health standards

Date.....Site.... Pt # Names of HRM currently Type of clinic..... Name of practitioner..... Role..... Any HRM-related risks Any other HRM interventions? *HRM Types Risk used or considered* discussed with patients? E.g. changes to other meds, (See list on right) Please give details. referral, call for advice ... Post operative 1 Anticoagulants bleeding E.g. Warfarin, Direct Oral Anti-Coagulants and Low Molecular Weight Heparins Postoperative 2 Antiplatelets bleeding E.g. aspirin, clopidogrel Anti-resorptive and anti-Medication Related 3 Jaw Osteo Necrosis angiogenic medicines E.g. bisphosphonates Hypoglycaemic medicines Diabetic complications, 4 e.g. hypoglycaemia E.g. insulin, metformin NSAIDs Interactions with other 5 E.g. ibuprofen or diclofenac medicines Paracetamol Overdose and toxicity 6 Antibiotics or Antifungal Interactions with other medicines medications

Dental High Risk Medicines (HRM) Data Collection Form



High risk medicines : Story so far Bleeds study

Count of Bleeds Bleed descriptor Intracerebral Upper GI Lower GI Unspecified	Bleed descriptor18-Intracerebral29Upper GI720Lower GI84		93 852 61 4866 40 518		TOTAL 1145 12127 1358 2669		Age Group 75+ 585 2394 299 812
		Type of bleed causing death				Annual admissions	
	Intracra	anial	Upper GI	Lower GI	Unspecified		
No drugs of interest	130		30	1	20	6364	
Anti-acid only	Anti-acid only			9	0	9	4893
Aspirin +/- NSAID only	52		10	0	6	1299	
Aspirin +/- NSAID + anti-acid on	Aspirin +/- NSAID + anti-acid only			9	0	7	2434
Other antiplatelets +/- anti-acid	48		3	0	10	903	
Aspirin + other antiplatelets onl	2		0	0	0	85	
Aspirin + other antiplatelets + anti-acid only		2		0	0	0	171
Anticoagulant + (aspirin/NSAIDs/other antiplatelet)		0		1	0	2	76
Anticoagulant + (aspirin/NSAIDs/other antiplatelet) + anti-acid only		2		1	0	1	153
Total		295	5	63	1	55	16378



Polling Question 2

What should we do next with high risk medicines?

- a. Develop a medicines-related "intracranial bleed" bundle
- b. Challenge Boards to reduce all medicines-related bleeds by x%
- c. Both of the above
- d. Develop other high risk medicines targets
- e. Other (please type in chat box)







Engaging the drivers for change from Feb 2018

- **Patient empowerment**: Not sure just ask? Signage in superstores?
- Work processes: Electronic alerts, polypharmacy review
- Education: Reframing HRM by actual harms rather than PK/PD?
- **Recognition for excellence**: Celebrating teams with best results WebEx, other forums
- **QI support**: SPSP Meds as QI support vs facilitator for learning network
- Digital [IT] systems: Using ISD and prescribing data, electronic alerts, HEPMA







Successes and Challenges

Successes:

- Enthusiastic network
- Data demonstrate HRM not just drugs with narrow therapeutic indices
- Intracranial bleeds, dental work, etc provide new avenues for innovation

Challenges:

- Utility of frameworks still to be demonstrated
- Risk of dissipation if tangible results not achieved
- Facilitating local prioritisation







- High risk medicines should be defined based upon frequency of actual harms, rather than pharmacological properties alone
- SPSP Medicines and our stakeholders are engaged in developing comparable data on specific harms, simple tools for measurement, and frameworks to help recognise risks and design improvements
- As a group we need to work on identifying and implementing effective interventions to reduce harms from high risk medicines from diverse settings







Any Questions?







WebEx Series

Patient empowerment

Education

QI support

Work processes

Recognition for excellence

Digital [IT] systems









Webex Series 2018/2019

Date	Time	Presenters	Торіс
Thursday 18 th October	3pm – 4pm	NHS Greater Glasgow & Clyde, NHS Western Isles and NHS Orkney	Using a QI approach to reducing omitted medicines (in collaboration with Excellence in Care)
Thursday 8 th November	3pm – 4pm	NHS Greater Glasgow & Clyde	Digital solutions to reduce medicines transcription







Transitions, Omissions and High Risk Medicine WebEx Series 2018-2019

Using a QI approach to reducing omitted medicines EiC test sites and SPSP Medicines team

Thursday 18 October 2018 3pm-4pm



@SPSPMedicines PSPMeds

As part of Healthcare Improvement Scotland's Ihub, SPSP activities support the provision of safe, high quality care, whatever the setting



See you on 18th October.....

spsp-medicines.hcis@nhs.net

http://ihub.scot/spsp/medicines/







Looking forward to welcoming you to...



Glasgow 2019 FORUM